Education
About Us
Working with TipRanks
Follow Us
Biontech Se Sponsored Adr (BNTX)
:BNTX
Earnings Data
Report Date
Aug 04, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-2.9Last Year’s EPS
-3.36Same Quarter Last Year
Strong Buy
Based on 18 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 05, 2025
|% Change Since: -7.31%
|Next Earnings Date:Aug 04, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a company that is making significant progress in its oncology programs and maintaining a strong financial position, despite experiencing decreased revenue and a higher net loss. The strategic investments in developing new therapies and preparing for future product launches are promising, but the financial losses and settlement expenses are notable challenges.Company Guidance
In BioNTech's first quarter 2025 earnings call, the company provided guidance on several key metrics. They reported total revenues of approximately €183 million for the quarter, primarily from COVID-19 vaccine sales, compared to €188 million in the first quarter of 2024, reflecting expected seasonality. BioNTech's research and development expenses reached €526 million, up from €508 million in the prior-year period, driven by the advancement of late-stage clinical studies, including those for BNT327. Selling, general, and administrative expenses were €121 million, down from €133 million due to reduced external services. The company recorded a net loss of €416 million, compared to a €315 million loss in the same period last year, with a basic and diluted loss per share of €1.73 versus €1.31 previously. BioNTech ended the quarter with a strong cash position of €15.9 billion, despite significant outflows related to acquisitions and settlements. For the full year, BioNTech reaffirmed its 2025 financial guidance, projecting revenues between €1.7 billion and €2.2 billion, R&D expenses from €2.6 billion to €2.8 billion, SG&A expenses between €650 million and €750 million, and capital expenditures ranging from €250 million to €350 million.Advancements in Oncology Programs
BioNTech presented new clinical data for their bispecific immunomodulator BNT327 and mRNA cancer immunotherapies, showing potential to establish new standards of care in oncology. They are advancing towards commercialization with the first BLA submission for BNT323 planned by the end of 2025.
COVID-19 Vaccine Developments
BioNTech is preparing for a variant-adapted COVID-19 vaccine rollout and maintains a strong financial position to support these developments.
Strong Financial Position
Despite a net loss, BioNTech ended the quarter with €15.9 billion in total cash plus security investments, indicating robust financial health.
---
BNTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BNTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2025 | $104.94 | $101.10 | -3.66% |
Mar 10, 2025 | $108.78 | $105.35 | -3.15% |
Nov 04, 2024 | $111.48 | $108.97 | -2.25% |
Aug 05, 2024 | $82.01 | $78.36 | -4.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Biontech Se Sponsored Adr (BNTX) report earnings?
Biontech Se Sponsored Adr (BNTX) is schdueled to report earning on Aug 04, 2025, TBA Not Confirmed.
What is Biontech Se Sponsored Adr (BNTX) earnings time?
Biontech Se Sponsored Adr (BNTX) earnings time is at Aug 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BNTX EPS forecast?
BNTX EPS forecast for the fiscal quarter 2025 (Q2) is -2.9.
---
